GLP-1 Agonists for Chronic Kidney Disease (CKD)
Thanks for listening to The Peptide Podcast.
Imagine a treatment that not only helps manage diabetes but also holds the potential to reverse kidney failure — what was once thought to be impossible. The recent FLOW study has remarkable groundbreaking evidence that GLP-1 receptor agonists can significantly improve kidney function in chronic kidney disease (CKD) patients. And while researchers try to understand the full implications of these findings, one thing is clear: the landscape of kidney disease treatment may never be the same again.
Read the Full Episode Transcript…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.